Cigarette smoke is an important environmental factor associated with a wide array of public health concerns. Acrolein, a component of tobacco smoke and a known toxin to various cell types, may be a key pathological factor mediating the adverse effects linked with tobacco smoke. Although acrolein is known to accumulate in the respiratory system after acute nasal exposure, it is not clear if it accumulates systemically, and less is known in the nervous system. The aim of this study was to assess the degree of acrolein accumulation in the circulation and in the spinal cord following acute acrolein inhalation in mice. Using a laboratory-fabricated inhalation chamber, we found elevated urinary 3-HPMA, an acrolein metabolite, and increased acrolein adducts in the spinal cord after weeks of nasal exposure to acrolein at a concentration similar to that in tobacco smoke. The data indicated that acrolein is absorbed into the circulatory system and some enters the nervous system. It is expected that these findings may facilitate further studies to probe the pathological role of acrolein in the nervous system resulting from smoke and other external sources.
INTRODUCTION
Cigarette smoking is one of the most prominent and preventable causes of illness in the United States [1] . It is associated with a wide array of public health concerns including cancer [2] , cardiovascular disease [3] , and pulmonary disease [4] . Consequently, much effort has been made to identify compounds responsible for the adverse effects of smoking and the list continues to grow [5] . Acrolein is a known cytotoxin produced by burning tobacco, and is capable of inflicting serious harm in the respiratory system [6] [7] [8] . Long-term (years) cigarette smoking can result in signifi cant systemic accumulation of acrolein in humans [9] .
However, it is not yet clear if acute smoking leads to a similar buildup of acrolein. In addition, the degree of adverse effects of cigarette-derived acrolein on the nervous system, either acute or long-term, has not yet been fully elucidated; only correlative clinical studies are available, and animal models have been insufficiently investigated.
This uncertainty has hindered the understanding of the adverse effects of smoking on neurodegenerative diseases and trauma.
Acrolein, a well-known component of tobacco smoke [10] , is a pro-inflammatory and pro-oxidative stress aldehyde [11, 12] , and is known to damage proteins, DNA, and lipids in various cell types including neurons, hepatocytes, epithelial cells, cardiac muscle cells, and kidney cells [4, [12] [13] [14] [15] [16] [17] [18] .
In addition, acrolein has been linked to cancer [8, [19] [20] [21] [22] , spinal cord trauma [11, [23] [24] [25] [26] , Alzheimer's disease [27] [28] [29] , amyotrophic lateral sclerosis [30] , multiple sclerosis [31] , and even aging [32] and pollution [33, 34] . Considering this, we speculated that acrolein generated by cigarette smoking could serve as a signifi cant neuropathological factor. Along with other known toxins, either synergistically or additively, acrolein could adversely infl uence the function of the nervous system, as has already been demonstrated in a variety of other organs such as the heart, kidney, lung, and liver [15, 16] . To discern the specifi c pathological role of cigarette-derived acrolein in the nervous system, it is critical to elucidate the effi ciency of its systemic absorption with respiratory exposure. However, despite the clinical observations of an increased acrolein metabolite among smokers [9, 35] , and the acute accumulation of acrolein in the respiratory system in both human and animal studies [36] [37] [38] , no animal or clinical correlative study has been conducted linking acute exposure to systemic accumulation. Consequently, quantification of systemic absorption and accumulation of acrolein following inhalation has yet to be ascertained.
To this end, the current study tested the hypothesis that acute nasal exposure to acrolein can cause its accumulation within the circulatory system in a mouse model, with a particular interest in the possibility of acrolein accumulation in the nervous system in light of its emerging recognition as a pathological factor in both neuronal trauma and degenerative diseases [11, 12] .
MATERIALS AND METHODS

Experimental Animals
This study was approved by and carried out in accordance 
Gas Chromatography/Mass Spectrometry
Analysis was performed using a Pegasus 4D gas 
Dot Immunoblotting
The extracted spinal cord segments were incubated with 1% Triton X and protease inhibitor cocktail at a 100:1 ratio (Sigma-Aldrich, St. Louis, MO) and homogenized with a glass homogenizer (Kontes Glass Co., Vineland, NJ). The sample was then incubated on ice for at least 1 h, followed by centrifugation at 13 500g for at least 30 min at 4°C.
Samples were stored at -80°C. One additional round of centrifugation at 13 500g was performed after removal from storage.
Prior to analysis, BCA protein assays were performed to ensure equal loading. Samples were transferred simultaneously to a nitrocellulose membrane using a BioDot SF microfiltration apparatus (Bio-Rad, Hercules, CA). Laboratories, Burlingame, CA) for 1 h at room temperature.
The membrane was then washed three times (10 min each) in blocking buffer followed by 0.1% Tween 20 in Trisbuffered saline before being exposed to Bio-Rad ImmunoStar substrate and visualized by chemiluminescence.
The density of dots was evaluated using ImageJ (NIH, Bethesda, MD).
3-HPMA Quantifi cation in Urine
Urine was collected using a metabolic cage (Fig. 2B ).
Specifically, ~1 mL was collected in a period of 12 h once per week. The urine was then stored at -80°C until analysis. 3-Hydroxypropyl mercapturic acid (3-HPMA) was measured in urine according to the description by Eckert et al. [39] and our previous publication [40] . Solid phase extraction with Isolute ENV+ cartridges (Biotage, Charlotte, NC) was used to prepare each sample before LC/MS/MS analysis.
Each cartridge was conditioned with 1 mL methanol, followed by 1 mL water, then 1 mL 0.1% formic acid in water. A volume of 500 μL urine was spiked with 200 ng 
Creatinine Measurement
Creatinine was measured using a creatinine (urinary) assay kit (Cayman Chemical Co., Ann Arbor, MI) described in detail in a prior publication [40] . A creatinine standard curve was constructed with known amounts of creatinine provided with the assay kit.
Statistical Analysis
Unless otherwise specified, one-way ANOVA followed by post-hoc Tukey's test was used for statistical analyses. P < 0.05 was considered statistically signifi cant. To the best of our knowledge, this is the fi rst evidence that acute acrolein inhalation at a level corresponding to cigarette smoke results in circulatory accumulation of acrolein, absorption by the nervous system, and excretion in urine as 3-HPMA in mice. These data are consistent with previous observations that human smokers tend to have higher levels of urinary 3-HPMA [9, 35] . Considering the established toxicity of acrolein in animal studies and its close association with human pathological conditions [12, 15, 16, 26, 41] , these fi ndings facilitate future investigations of its adverse effects on various functions resulting from smoke and other external sources.
RESULTS AND DISCUSSION
3-HPMA is elevated in human smokers to a level that is 5-10 times of that of non-smokers [9, 35] . However, most The use of 3-HPMA to monitor systemic acrolein changes provoked by smoking has been mainly limited to human studies [9, 35] . We used an acrolein concentration of 1.5 ppm which is well below the upper limit estimated for tobacco smoke (50-70 ppm) [42, 43] , and within the well-established dose range used in previous studies [37, [43] [44] [45] . We also used a paradigm of two 30-min exposures per day. Assuming each cigarette lasts for 5 min, a 60-min acrolein exposure is equivalent to consuming 12 cigarettes per day. According to the Center for Disease Control, an average smoker consumes 20 cigarettes per day [46] . So, the time of Although absorbed through the respiratory tract in the current study, an increase in acrolein concentration was not limited to urine, but was also found in the spinal cord where acrolein is associated with pathological events [11, 12, 23-26, 40, 47] .
Since spinal cord-related neurodegenerative disease and trauma have been linked to acrolein [12] , its increase due to smoke could play an important role in the pathology of these conditions and this deserves further investigation.
Here, we demonstrated local acrolein absorption into the spinal cord after inhalation. Studies may further elucidate the differential accumulation of acrolein in other tissues in vivo, including but not limited to the brain, the peripheral nervous system, and other organs such as the heart, liver and kidney.
The importance of acrolein accumulation after shortterm inhalation is not clear. Acrolein increased two weeks after respiratory exposure and remained high for at least another week before the experiment was terminated. Based on our in vitro study, at a low micromolar level, acrolein causes time-dependent toxicity and more importantly, evident cellular damage of neurons results from only a few hours of exposure [47] [48] [49] [50] [51] [52] . Therefore, it is likely that acute accumulation of acrolein through inhalation can inflict signifi cant cellular damage. It is also reasonable to assume that the longer the insult persists, the more likely acrolein damage is to progress and eventually lead to cell death. If so, a longer duration of smoking may correspond with more severe neural injury.
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